| pubmed-article:8556189 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8556189 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8556189 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:8556189 | lifeskim:mentions | umls-concept:C0042514 | lld:lifeskim |
| pubmed-article:8556189 | lifeskim:mentions | umls-concept:C0114771 | lld:lifeskim |
| pubmed-article:8556189 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8556189 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8556189 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8556189 | pubmed:dateCreated | 1996-2-28 | lld:pubmed |
| pubmed-article:8556189 | pubmed:abstractText | Dofetilide is a new antiarrhythmic agent with potent IK blocking properties in vitro. We developed a dose-ranging, placebo-controlled study design to define the range of effective doses and to evaluate the clinical electrophysiology of intravenous dofetilide in patients in whom sustained ventricular tachycardia or fibrillation was reproducibly inducible at baseline electrophysiologic testing. | lld:pubmed |
| pubmed-article:8556189 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8556189 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8556189 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8556189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8556189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8556189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8556189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8556189 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8556189 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8556189 | pubmed:issn | 1045-3873 | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:KeyI DID | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:FriedrichTT | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:RodenD MDM | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:EchtD SDS | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:MurrayK TKT | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:VorperianVV | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:BorganelliS... | lld:pubmed |
| pubmed-article:8556189 | pubmed:author | pubmed-author:CrawfordD MDM | lld:pubmed |
| pubmed-article:8556189 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8556189 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:8556189 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8556189 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8556189 | pubmed:pagination | 687-99 | lld:pubmed |
| pubmed-article:8556189 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:meshHeading | pubmed-meshheading:8556189-... | lld:pubmed |
| pubmed-article:8556189 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8556189 | pubmed:articleTitle | A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. | lld:pubmed |
| pubmed-article:8556189 | pubmed:affiliation | Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. | lld:pubmed |
| pubmed-article:8556189 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8556189 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8556189 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8556189 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8556189 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8556189 | lld:pubmed |
